Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S157000
Reexamination Certificate
active
10080503
ABSTRACT:
Novel non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.
REFERENCES:
patent: 3919238 (1975-11-01), Spencer et al.
patent: 4460475 (1984-07-01), Hayatsu et al.
patent: 4623638 (1986-11-01), Hayatsu et al.
patent: 4777052 (1988-10-01), Weisberger et al.
patent: 4981784 (1991-01-01), Evans et al.
patent: 5011697 (1991-04-01), Jones et al.
patent: 5071773 (1991-12-01), Evans et al.
patent: 5179202 (1993-01-01), Gross
patent: 5576324 (1996-11-01), Kyotani et al.
patent: 5677336 (1997-10-01), Jones et al.
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5994544 (1999-11-01), Jones et al.
patent: 6001846 (1999-12-01), Edwards et al.
patent: 6017924 (2000-01-01), Edwards et al.
patent: 6030967 (2000-02-01), Mauri et al.
patent: 6093821 (2000-07-01), Jones et al.
patent: 6093826 (2000-07-01), Edwards et al.
patent: 6121450 (2000-09-01), Jones et al.
patent: 6172241 (2001-01-01), Edwards et al.
patent: 6180794 (2001-01-01), Edwards et al.
patent: 6340704 (2002-01-01), Mauri et al.
patent: 6448405 (2002-09-01), Jones et al.
patent: 6462038 (2002-10-01), Higuchi et al.
patent: 6534516 (2003-03-01), Edwards et al.
patent: 6566372 (2003-05-01), Zhi et al.
patent: 6667313 (2003-12-01), Hamann et al.
patent: 6696459 (2004-02-01), Jones et al.
patent: 2002/0183346 (2002-12-01), Zhi et al.
patent: 2003/0130505 (2003-07-01), Zhi et al.
patent: 2003/0149268 (2003-08-01), Hamann et al.
patent: 2003/0186970 (2003-10-01), Higuchi et al.
patent: 24 27 409 (1975-01-01), None
patent: 0 638 571 (1993-04-01), None
patent: 50-25595 (1975-03-01), None
patent: 03-282445 (1991-12-01), None
patent: 07-013017 (1995-01-01), None
patent: 3047434 (2000-05-01), None
patent: 95/11215 (1995-04-01), None
patent: 96/19458 (1996-06-01), None
patent: WO 97/49709 (1997-12-01), None
patent: 00/12502 (2000-03-01), None
patent: 01/16108 (2001-03-01), None
patent: 01/16133 (2001-03-01), None
patent: 01/16139 (2001-03-01), None
patent: 02/066475 (2002-08-01), None
patent: 02/068427 (2002-09-01), None
patent: 2005/018573 (2005-03-01), None
Simental et al., “Transcriptional Activation and Nuclear Targeting Signals of the Human Androgen Receptor,”Journal of Biological Chemistry,266(1), 510-518 (Jan. 5, 1991).
Berger et al., “Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor,”J. of Steroid Biochem. and Molecular Biol. 41(3-8), 733-738 (Mar. 1992).
Rosen et al., “Intracellular Receptors and Signal Transducers and Activators of Transcription Superfamilies: Novel Targets for Small-Molecule Drug Discovery,” Journal of Medicinal Chemistry, 38(25), 4855-4874 (Dec. 8, 1995).
Gruber et al., “Topical Cyproterone Acetate Treatment in Women with Acne,” Archives of Dermatology, 134, 459-463 (Apr. 1998)††.
Venturoli et al., “A Prospectiove Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism,” Journal Clinical Endocrinology & Metabolism, 84(4), 1304-1310 (1999)††.
Rosen et al., “Intracellular Receptors and Signal Transducers and Activators of Transcription Superfamilies: Novel Targets for Small-Molecule Drug Discovery,”Journal of Medicinal Chemistry, 38(25), 4855-4874 (Dec. 8, 1995)††.
Evans, R., “The Steroid and Thyroid Hormone Receptor Superfamily,”Science, 240:889-895 (May 13, 1988).
Hamann, L., et al., “Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines,”J. Med. Chem., 41:623-639, (WEB publ. date: Jan. 22, 1998).
Edwards, J., et al., “New Nonsteroidal Androgen Receptor Modulators Based on 4-(Trifluoromethyl)-2(1H)-Pyrrolidino[3,2-g]Quinolinone,”Bioorganic&Medicinal Chemistry Letters, 8:745-750 (1998).
Edwards, J., et al., “Nonsteroidal Androgen Receptor Agonists Based on 4-(Trifluoromethyl)-2H- Pyrano[3,2-g]Quinolin-2-One,”Bioorganic&Medicinal Chemistry Letters, 9:1003-1008 (1999).
Higuchi, R., et al., “4-Alkyl- and 3,4-Dialkyl-1,2,3,4-Tetrahydro-8-Pyridono[5,6-g]Quinolines: Potent, Nonsteroidal Androgen Receptor Agonists,”Bioorganic&Medicinal Chemistry Letters, 9:1335-1340 (1999).
Jones, G.,Comprehensive Heterocyclic Chemistry, Katritzky, A.R.; Rees, C.W., eds. Pergamon, New York, 1984, vol. 2, Chap. 2.08, pp. 421-426.
Fujisaki, S., et al., “Halogenation UsingN-Halogenocompounds. I. Effect of Amines onortho- Bromination of Phenols with NBS,”Bull. Chem. Soc. Jpn., 66:1576-1579, (May 1993).
Wagaw, S., et al., “Palladium-Catalyzed Coupling of Optically Active Amines with Aryl Bromides,”J. Am. Chem. Soc., 119:8451-8458; Absr. Publ. Aug. 15, 1997.
Allegretto, E. A. and R.A. Heyman, “Intracellular receptor characterization and ligand screening by transactivation and hormone-binding assays,” Methods in Molecular Genetics vol. 8: Human Molecular Genetics, pp. 405-420 (1996).
Croston et al., “Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes,” Endocrinology, 138(9):3779-3786 (1997).
Hamann, “Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071),” Journal of Medicinal Chemistry, 42(2):210-212 (1999).
Kong et al., “Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quinolines,” Bioorganic & Medicinal Chemistry Letters, 10(5)::411-414 (2000).
Lamb, P. and J. Rosen, “Drug discovery using receptors that modulate gene expression,” Journal of Receptor & Signal Transduction Research, 17(1-3): 531-543 (1997).
Lawson et al., “Androgen responsiveness of the pituitary gonadotrope cell line LβT2,” Journal of Endocrinology, 170(3):601-607 (2001).
McDonnell et al., “Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors,” Seminars in Cancer Biology, 5(5):327-336 (1994).
Miner, J. N. and C. M. Tyree, “Drug discovery and the intracellular receptor family,” Vitamins and Hormones, 62: 253-280 (2001).
Negro-Vilar, A., “Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium,” Journal of Clinical Endocrinology and Metabolism 84(10):3459-3462 (1999).
Rosen et al., “Intracellular receptors and signal transducers and activators of transcription superfamilies: Novel targets for small-molecule drug discovery,” Journal of Medicinal Chemistry, 38(25):4855-4874 (1995).
Rosen, J. and A. Negro-Vilar, “Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile,” Journal of Musculoskeltal and Neuronal Interactions, 2(3):222-224 (2002).
Santiso-Mere, D. and D.P. McDonnell, “Applied nuclear receptor research in the drug discovery process,” Chimicaoggi/Chemistry Today 12(5-6):29-36 (1994).
Zhi, L. and E. Martinborough, “Selective androgen receptor modulators (SARMs),” Chapter 17 in Annual Reports in Medicinal Chemistry 36:169-180 (2001).
Zhi et al., “Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone,” Bioorganic
Adams Mark E.
Caferro Thomas R.
Chen Jyun-Hung
Cummings Marquis L.
Deckhut Charlotte L. F.
Crane L. E.
Fish & Richardson P.C.
Ligand Pharmaceuticals Incorporated
Miskiel Frank J.
Seidman Stephanie
LandOfFree
Tricyclic quinolinone and tricyclic quinoline androgen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic quinolinone and tricyclic quinoline androgen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic quinolinone and tricyclic quinoline androgen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3799709